|Year||# Div.||Div. Paid||Div. Yield||Jan||Feb||Mar||Apr||May||Jun||Jul||Aug||Sep||Oct||Nov||Dec|
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; and PADCEV, an ADC composed of an anti-Nectin-4 monoclonal antibody for the treatment of metastatic urothelial cancers. It also develops Tucatinib, an investigational oral, small molecule TKI for HER2, a growth factor receptor; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. In addition, the company develops ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SEA-BCMA, a clinical-stage non-fucosylated BCMA-directed antibody for patients with relapsed or refractory multiple myeloma. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; biotechnology and pharmaceutical companies; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
The current Price to Earnings Ratio of Seagen is 41.3.
The PE Ratio is calcluated by dividing the current Seagen share price (153.4 USD) by the earnings per share (3.4).
The current market cap of Seagen is 25.2 B USD.
The current stock price of Seagen is 153.4 USD.
The ISIN (International Securities Identification Number) of Seagen is US81181C1045.
The ticker symbol of Seagen is SGEN.
The address of the Seagen HQ is Building 3, 98021 Bothell, WA, USA.